Just days after Telix priced a $200 million initial public offering (IPO) in the US, the Australian radiopharmaceutical specialist has abandoned the plan. In a statement, Telix said that “current market conditions” have made it reconsider the move, given the proposed Nasdaq listing “was not predicated on the need to raise capital.”
